Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

53.46 +0.15 (+0.28%)
Official Closing Price Updated: 7:00 PM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
News headline image
2 Dividend Stocks to Double Up on Right Now ↗
These dividend growth machines could have considerable upside for long-term investors. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
The Smartest Dividend Stocks to Buy With $1,000 Right Now ↗
Here are three stocks offering attractive yields of up to 4.9%, each backed by strong businesses. 
Via The Motley Fool
Topics Economy Intellectual Property
News headline image
Which S&P500 stocks are moving on Friday? ↗
Stay informed about the performance of the S&P500 index one hour before the close of the markets on Friday. Uncover the top gainers and losers in today's session for valuable insights. 
Via Chartmill
News headline image
Why Bristol-Myers Squibb (BMY) Stock Is Up Today
Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) jumped 2.6% in the afternoon session after an analyst at Guggenheim upgraded the company's stock from "Neutral" to "Buy" and set a... 
Via StockStory
Topics Artificial Intelligence Supply Chain
News headline image
Top S&P500 movers in Friday's session ↗
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Friday as we examine the latest happenings in today's session. 
Via Chartmill
News headline image
The Best Turnaround Stock to Invest $1,000 in Right Now ↗
Pfizer and Bristol Myers Squibb are deeply out-of-favor drugmakers, but one could be the better turnaround candidate if you think long term. 
Via The Motley Fool
News headline image
U.S. Food and Drug Administration (FDA) Grants Priority Review to Bristol Myers Squibb's Application for Opdivo® (nivolumab) Plus Chemotherapy Combination for Classical Hodgkin Lymphoma
From Bristol Myers Squibb
Via Business Wire
News headline image
Great Rotation: Tech Exodus Fuels Dow's Record Run While Nasdaq Struggles
As of December 12, 2025, the financial markets are witnessing a significant "Great Rotation," a pronounced shift of capital from high-growth technology and Artificial Intelligence (AI) stocks to more... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
3 Unpopular Stocks with Questionable Fundamentals
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
Bristol Myers Squibb Announces Dividend Increase
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Pharmaceutical Stocks to Buy at a Discount ↗
Investors are currently so focused on one type of drug that even good companies are being left on the sidelines. 
Via The Motley Fool
Topics Intellectual Property
News headline image
1 Large-Cap Stock on Our Buy List and 2 We Turn Down
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for... 
Via StockStory
News headline image
Bristol Myers Squibb Advances Lymphoma Research with New Targeted Protein Degradation and Cell Therapy Data at ASH 2025
From Bristol Myers Squibb
Via Business Wire
News headline image
Do These 3 Healthcare Stocks Need a Checkup? ↗
These three drugmakers are all well off their recent highs. Is this a sign of opportunity or risk? 
Via The Motley Fool
Topics Intellectual Property
News headline image
Bristol Myers Squibb’s Breyanzi Approved by the U.S. FDA as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Marginal Zone Lymphoma (MZL)
From Bristol Myers Squibb
Via Business Wire
News headline image
3 Stocks Under $50 We’re Skeptical Of
Stocks in the $10-50 range offer a sweet spot between affordability and stability as they’re typically more established than penny stocks. But their headline prices don’t guarantee quality, and... 
Via StockStory
News headline image
Which S&P500 stocks are moving on Wednesday? ↗
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Wednesday. 
Via Chartmill
News headline image
What's going on in today's session: S&P500 movers ↗
Stay updated with the movements of the S&P500 index in the middle of the day on Wednesday. Discover which stocks are leading as top gainers and losers in today's session. 
Via Chartmill
News headline image
Bristol Myers Stock Jumps As Wall Street Backs Added Enrollment In Alzheimer’s Trial — Retail Calls It ‘Worth A Play’ ↗
Bristol Myers’ ADEPT-2 update drew support from JPMorgan and William Blair following the decision to continue the study with added enrollment. 
Via Stocktwits
News headline image
These S&P500 stocks are moving in today's pre-market session ↗
Let's have a look at what is happening on the US markets before the opening bell on Wednesday. Below you can find the top S&P500 gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Bristol Myers Squibb Announces Continuation of ADEPT-2 Phase 3 Study in Psychosis Associated with Alzheimer's Disease
From Bristol Myers Squibb
Via Business Wire
News headline image
Amazon Unleashes AI Frontier Agents: A New Era of Autonomous Digital Workers
Amazon (NASDAQ: AMZN) has unveiled a groundbreaking class of AI agents, dubbed "frontier agents," capable of operating autonomously for extended periods—even days—without constant human intervention.... 
Via TokenRing AI
Topics Artificial Intelligence Economy
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
Via Investor Brand Network
Topics Government
News headline image
Chronic Rare Diseases in an Aging America: Why HyBryte and Federal Policy Matter Now
From BioMedWire
Via GlobeNewswire
News headline image
Bristol-Myers Squibb Co (NYSE:BMY) Presents a Compelling Value Investment Case ↗
Bristol-Myers Squibb (BMY) presents a value investment case, trading at a deep discount with strong earnings power and a high dividend amid near-term challenges. 
Via Chartmill
News headline image
Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio
From Bristol Myers Squibb
Via Business Wire
News headline image
2 Undervalued, High-Quality Companies to Buy Now and Hold Forever ↗
If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive. 
Via The Motley Fool
Topics Intellectual Property
News headline image
2 Top Dividend Stocks to Buy and Hold ↗
Patience will be rewarded for those who stick with these two healthcare stocks. 
Via The Motley Fool
Topics Artificial Intelligence Intellectual Property
News headline image
Should You Buy Bristol Myers Stock for Its 5.4%-Yielding Dividend? ↗
The pharma stock yields more than 4x the S&P 500 average. 
Via The Motley Fool
Topics Intellectual Property Stocks
News headline image
Bristol-Myers (BMY) Earnings Call Transcript ↗
Bristol-Myers (BMY) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.